Burden of arthritis is soaring in the USA, says experts

14 January 2008

Arthritis is exploding in an aging population of US baby boomers and is projected to increase by 40% in the next two decades, according to a new study released by the Centers for Disease Control and Prevention (CDC) for the National Arthritis Data Workgroup. The report reaffirms that nearly one in five US adults (46 million people) have arthritis and an estimated 67 million citizens will be affected by 2030.

The study, published in the January issue of Arthritis & Rheumatism, found that osteoarthritis, the most common form of this disease, has increased to 27 million people, up from 1990 estimates of 21 million. Other key findings of the report include an increase in gout (three million adults, up from 2.1 million) and a decrease in rheumatoid arthritis (down from 2.1 million adults to 1.3 million). The study also estimates that 294,000 American children and teenagers under the age of 18 (or one in 250 children) have been diagnosed with arthritis or another rheumatologic condition.

"The prevalence of arthritis overall continues to grow in the United States, which is not surprising given that many of the specific conditions are age related and the general population is aging," said Charles Helmick, a CDC epidemiologist and a lead author on the study. "Increases in some of the more common types of arthritis suggest a growing impact on the health care and public health systems," Dr Helmick added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight